NI-004 is under clinical development by Neurimmune and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NI-004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Recommended Buyer's Guides
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NI-004 overview
NI-004 is under development for the treatment of Alzheimer's disease. It was also under development for lewy body dementia. The drug candidate is developed based on Reverse Translational Medicine (RTM) technology platform. It acts by targeting muscarinic acetylcholine receptor.
Neurimmune overview
Neurimmune, formerly Neurimmune Therapeutics is a biopharmaceutical company that develops immunotherapeutics for human diseases. The company’s pipeline products include human-derived monoclonal antibodies developed for the treatment and prevention of human neurodegenerative disorders through preclinical development. It develops a reverse translational medicine technology platform which creates recombinant human-derived monoclonal antibodies as therapeutics. Neurimmune’s human-derived monoclonal antibodies are used as drug candidates in the treatment of diseases such as Alzheimer’s disease, Parkinson’s disease, central nervous system disorders, transthyretin amyloidosis, type-2 diabetes, tauopathies and amyotrophic lateral sclerosis. The company also conducts research and development programs on progressive multifocal leukoencephalopathy, neuropathy, Huntington’s disease and cardiomyopathy. Neurimmune is headquartered in Zurich, Switzerland.
For a complete picture of NI-004’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
